Cadrenal Therapeutics, Inc. (CVKD) relative valueRV
CVKD's return on equity of -483.3% ranks in the 31st percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
Kresmion ranks CVKD against its industry peers from annual SEC filings and market-price snapshots.
Against 19 Biotechnology peers
| Metric | CVKD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 131K USD | n/a | 11 |
| Revenue YoY | n/a | n/a | n/a | 1 |
| Gross margin | n/a | 58.1% | n/a | 8 |
| Operating margin | n/a | -5143.5% | n/a | 10 |
| Net margin | n/a | -4911.4% | n/a | 10 |
| Return on equity | -483.3% | -212.7% | 31st | 17 |
| P / E | n/a | n/a | n/a | n/a |
| 1 year | -92.9% | -93.9% | 58th | 12 |
Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Fiscal periods ending between 2025-12-31 and 2026-06-30. Prices as of 2026-10-14. Every fundamental figure is one full fiscal year from one filing. Nothing is trailing twelve months and nothing is converted between currencies. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above. 0001213900-26-036946
Peer set, 19 companies
ONCO, SXTP, MBIO, HCWB, APVO, REVB, JUNS, BRTX, PPCB, CLDI, ADTX, MTNB, VIVS, SILO, GOVX, ERNA, GRI, PMCB, PCSA
Left out: MLEC (period gap), XRTX (no annual filing), NYMXF (period gap), VCNX (period gap), LSBCF (period gap), VRAX (period gap).
What could not be compared
- 58 The filer did not report this line in the filing used.
- 12 The denominator is zero or negative, so the ratio has no meaning.
- 6 The latest close times the filed share count disagrees with the company's market cap by more than a split-sized factor, so price and the filing are not on one share basis.
- 5 The price series does not reach back to the start of this window.
- 5 This company's fiscal year ends more than 200 days from the subject's, so it is a different economic year.
- 5 The share price jumped by a stock-split ratio after the filing this figure comes from, and no later filing has restated it on the new share basis yet, so price and per-share figures may be on different bases.
- 2 Fewer than 5 peers carry a comparable value, so no median, quartile or percentile is published.
- 2 The price series jumps by a factor of 4.0 or more inside this window, which is a corporate action the stored series does not restate.
- 1 Not meaningful: the prior year is zero, negative, or too small a base for a percentage to describe. Both figures are shown instead.
- 1 No annual filing (10-K, 20-F or 40-F) with fiscal-year figures.
Free account
Open the relative value desk with a free account
An account turns this page into a research desk: thirty-one metrics over the whole peer set instead of eight, the distribution behind each median, the metric's history against the peer band, an editable peer set, the filing behind every cell, and CSV. The table above stays free.
Cite this data
Every fundamental figure is the full fiscal year reported on one annual SEC filing (10-K, 20-F or 40-F), named by accession. Peers are the company's industry group: the GICS sub-industry where the company is GICS-classified, otherwise the data vendor's industry label (the two label sets are not merged). A median, quartile or percentile is published only when at least five peers carry a comparable value, and a peer reporting in another currency is excluded from a level rather than converted. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above.
Upstream: SEC EDGAR XBRL company facts
Kresmion, "CVKD relative value, Kresmion", data as of 2026-03-31, https://kresmion.com/tools/relative-value/CVKD. Upstream data: SEC EDGAR XBRL company facts.
Link to this data (HTML):
<a href="https://kresmion.com/tools/relative-value/CVKD">CVKD relative value, Kresmion (Kresmion)</a>